Connecting patients, carers, clinicians and scientists to improve life with aspergillosis

World Aspergillosis Day (WAD) is an annual global event that brings together people who live with, care for, treat, and research long-term forms of aspergillosis — particularly chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA).

Each year, WAD creates a shared space where:

  • patients and carers can hear directly from specialists,

  • clinicians and scientists can learn from patient experience,

  • and everyone can explore how new research translates into better care.

🎥 Missed previous events?
Recordings from earlier World Aspergillosis Day meetings are available on our YouTube channel.


📅 NAC World Aspergillosis Day Meeting 2026

The National Aspergillosis Centre (NAC) will once again host a free online meeting:

🗓 Tuesday 3 February 2026
💻 Online via Microsoft Teams
👥 Open to patients, carers, clinicians, scientists, and anyone who lives or works with aspergillosis

🧬 This year’s theme:

“How can the genomics revolution help patients with chronic aspergillosis?”


Why genomics — and why now?

Modern molecular tests such as PCR and DNA sequencing are becoming faster, cheaper and more accurate. Because of this, the NHS is increasingly exploring how genomic technologies can be used to improve diagnosis, monitoring and treatment across many diseases — including aspergillosis.

This year’s WAD meeting will start an open discussion between patients and professionals about which genomic and molecular tests are likely to matter most for people with aspergillosis in the years ahead.

Topics will include:

  • 🧠 Is there a “gene for aspergillosis”?
    Should people be tested for genetic susceptibility?

  • 💊 Genes and voriconazole dosing
    Can testing the CYP2C19 gene help personalise antifungal treatment?

  • 🦠 Tracking antifungal resistance
    How molecular testing of Aspergillus strains can help hospitals monitor resistance.

  • 🔬 Aspergillus PCR at NAC
    How PCR is already used to diagnose and monitor chronic aspergillosis.


🗣️ Patient voices at the heart of the meeting

As always, patient experience will be central to the day.

This year will include new patient stories, including Alison, who will talk about how her aspergillosis treatment led to the development of adrenal insufficiency, and what that has meant for her care and daily life.


“I don’t know anything about genetics — is this for me?”

Absolutely yes.

You don’t need any background in genetics to take part. Everything will be explained clearly, step by step, with minimal jargon.

Planned discussion topics include:

  • What do my Aspergillus PCR test results actually mean?

  • Is there really a “gene for CPA”?

  • Why do genes matter for antifungal dosing?

In fact, the more questions you ask — especially the “silly” ones — the better. The discussion from the day will be used to create a new patient leaflet, designed to help people better understand their diagnosis and test results.


✅ Registration is now open

🎟 Book your free place via Eventbrite:
👉 www.eventbrite.co.uk/e/world-aspergillosis-day-tickets-1980707139373


💻 Joining via Microsoft Teams

The meeting will be held online using Microsoft Teams, which you can download here:
👉 www.microsoft.com/en-gb/microsoft-teams/group-chat-software

If you haven’t used Teams before, we recommend doing a test call in advance. If you run into any problems setting things up, we’re very happy to help.


We hope you can join us for World Aspergillosis Day 2026 — to learn, to ask questions, and to help shape the future of aspergillosis care together.


When discharge from a specialist service is being discussed

A reassuring explanation for people with long-standing Aspergillus bronchitis

This page is for people who have lived for many years with a diagnosis of Aspergillus bronchitis, and who are now hearing that discharge from a specialist or tertiary service may be discussed, or is being gently considered.

Many patients tell us this brings up worries such as:

  • “Does this mean I’m less safe?”

  • “Does this mean they’re not sure anymore?”

  • “What if things get worse later?”

These feelings are very common, and they make sense.


First — nothing has been decided yet

If discharge is being discussed, it usually means:

  • Your team is reviewing your care carefully

  • They are looking at whether regular specialist follow-up is still helping right now

  • They are not withdrawing care, and not closing doors

Discussion is part of good medicine — especially with conditions that can change slowly over time.


Why might discharge even come up after many years?

This can feel surprising, but it is usually because:

  • Your condition has been stable for a long time

  • There has been no clear progression

  • Specialist treatments are not currently being changed

  • Ongoing follow-up may not be adding extra benefit at this stage

This is often a sign of relative stability, not doubt or disbelief.


Does this mean they think you never had Aspergillus bronchitis?

No — not at all.

What it usually means is:

  • Aspergillus bronchitis was a reasonable and helpful way to understand your symptoms at the time

  • Over time, the balance has shifted

  • Aspergillus may now be less active or less central to how you are feeling

Medical understanding evolves, and long-term conditions often change their shape rather than disappear or suddenly become “wrong”.


Does discharge mean Aspergillus is no longer important?

Not exactly.

It usually means:

“We don’t think Aspergillus is the main thing driving your symptoms right now.”

It does not mean:

“Aspergillus will never matter again.”

Your specialists know that Aspergillus-related problems can:

  • Fluctuate

  • Become more relevant during periods of illness or change

  • Need revisiting later on

That possibility is built into discharge planning, even if it is not always said clearly.


Why does this still feel unsettling?

Because specialist care often feels like a safety net.

You may have felt:

  • Known and understood by the team

  • Reassured by specialist oversight

  • Protected by regular review

Thinking about discharge can feel like losing that protection — even when nothing is actually changing day to day.

That emotional response is completely understandable.


What discharge from a specialist service usually does mean

If discharge does happen, it usually means:

  • Your care continues with your GP or respiratory team

  • Your history does not disappear

  • You are not starting from scratch

  • Re-referral is expected if things change

Specialist teams rarely intend discharge to be permanent or final.


What about being re-referred if things worsen?

This is one of the most important points — and a reassuring one.

In most cases:

  • Re-referral is anticipated

  • Patients previously known to the service are often reviewed more quickly

  • You do not need to “prove” everything again

Discharge usually comes with an open door, even if that door is not labelled as such.


What helps patients feel safer at this stage

It is reasonable to want:

  • A clear explanation of why discharge is being discussed

  • Reassurance that this is about now, not forever

  • Clarity about what would prompt a return

  • Confidence that your GP knows your history

These are normal needs — not demands.


What you might gently ask your team

You could ask:

  • “If my symptoms change, would re-referral be straightforward?”

  • “What sort of changes should prompt a review?”

  • “Will my GP have clear guidance from you?”

  • “Is discharge something we can review over time?”

These questions often help turn uncertainty into reassurance.


Key things to hold onto

  • Discussion of discharge usually reflects stability, not dismissal

  • It does not mean your past diagnosis was wrong

  • It does not mean you are being left unsupported

  • Re-referral is part of good planning, not failure

  • Feeling unsure or vulnerable at this point is very common


In gentle terms

Talking about discharge usually means “you are doing well enough not to need us right now” — not “you never needed us” and not “you’re on your own”.


Hyper-IgE syndrome

A patient-friendly guide (and why it matters if you have aspergillosis)

Hyper-IgE syndrome is a rare condition of the immune system. People with it have very high levels of an antibody called Immunoglobulin E (IgE), but their immune system does not work properly at fighting certain infections.

It is not the same as having lots of allergies, even though it can look very similar at first.


What is IgE, and why does it matter?

IgE is usually involved in allergies and asthma.

In Hyper-IgE syndrome:

  • IgE levels are extremely high (often many thousands)

  • But the immune system is unbalanced

  • This makes infections—especially in the lungs and skin—harder to control

So IgE is high, but protection is weak.


How might Hyper-IgE syndrome affect everyday life?

Not everyone has the same symptoms, but common features include:

Lung and chest problems

  • Repeated chest infections (often from a young age)

  • Ongoing cough, breathlessness and mucus

  • Lung damage such as bronchiectasis

  • Lung cavities that can later become infected by moulds such as Aspergillus

Skin and infection problems

  • Long-standing eczema or very sensitive skin

  • Recurrent skin infections or boils

  • Infections that keep coming back or take a long time to clear

Other clues (in some people)

  • Frequent infections in childhood

  • Bone or joint problems

  • Dental issues (for example baby teeth not falling out on time)


Why is this important for people with aspergillosis?

For many people, Aspergillus causes allergy or irritation.

In Hyper-IgE syndrome:

  • The immune system struggles to control moulds

  • Aspergillus can behave more like a true infection, not just an allergy

  • Lung damage can happen more easily and progress faster

This means doctors may need to:

  • Monitor lungs more closely

  • Treat fungal disease earlier and for longer

  • Be cautious with repeated or long-term steroid use

Specialist centres such as the National Aspergillosis Centre are often involved when aspergillosis and immune problems overlap.


Isn’t this just severe allergy or ABPA?

Hyper-IgE syndrome can look similar to:

  • Severe allergic asthma

  • Allergic Bronchopulmonary Aspergillosis (ABPA)

The key difference is that in Hyper-IgE syndrome:

  • The immune system itself is faulty

  • High IgE is part of a wider immune problem

  • Treating allergy alone may not be enough

Some people are treated for asthma or ABPA for years before this possibility is considered.


How is Hyper-IgE syndrome treated?

There is no single cure, but good treatment can make a big difference. The aim is to prevent infections, protect the lungs, and reduce symptoms.

1. Preventing infections (most important)

Because the immune system does not fight germs normally:

  • Some people take regular low-dose antibiotics

  • Others use antibiotics early and promptly when infections start

For people with aspergillosis:

  • Antifungal medicines may be needed

  • Monitoring is usually closer and longer-term


2. Protecting the lungs

Many people develop bronchiectasis or lung damage, so care often includes:

  • Airway clearance physiotherapy

  • Saline nebulisers to help clear mucus

  • Regular sputum tests

  • Early treatment of flare-ups

The goal is to stop the cycle of:

infection → inflammation → permanent lung damage


3. Managing inflammation and allergy (carefully)

People may also have asthma-like symptoms, eczema and multiple allergies.

  • Steroids can help symptoms, but long-term or frequent use can increase infection risk

  • Doctors usually try to keep steroid doses as low as possible

Biologic treatments (such as anti-IgE medicines):

  • May help some people

  • Do not fix the immune problem

  • Are considered on an individual basis, usually in specialist centres


4. Skin care

  • Regular moisturising

  • Prompt treatment of infected eczema

  • Good skin care helps reduce infection risk


How is Hyper-IgE syndrome diagnosed?

Diagnosis usually involves:

  • A detailed review of your medical history (often including childhood infections)

  • Blood tests of immune function

  • Referral to an immunology specialist

  • Sometimes genetic testing


Does having high IgE mean I definitely have this?

No.
Hyper-IgE syndrome is rare.

But it may be worth asking about if:

  • Your IgE has always been extremely high

  • You’ve had repeated infections for many years

  • You have bronchiectasis without a clear cause

  • Aspergillosis seems unusually persistent or severe

  • Standard asthma or allergy treatments don’t fully explain your symptoms


Key message

Very high IgE does not always mean “just allergy.”
In a small number of people, it reflects a deeper immune problem that changes how aspergillosis behaves and how it should be treated.

If your illness doesn’t quite fit the usual labels, it is reasonable to ask whether an immunology review would help.


January–February 2026 Aspergillosis Papers (week 3)

Grouped by relevance and impact


🟥 HIGH IMPACT / PRACTICE-RELEVANT

(Most important for patients, clinicians, and services)

1. Chronic Pulmonary Aspergillosis (CPA): outcomes and mortality

Clinical Features and Mortality of Chronic Pulmonary Aspergillosis in Brazil
Open Forum Infectious Diseases, Jan 2026

Why this is important

  • Large multicentre cohort

  • Real-world data from TB-endemic, resource-limited settings

  • Directly relevant to global CPA burden, including post-TB disease

Key messages

  • CPA carries substantial long-term mortality

  • Tuberculosis is a major driver of CPA worldwide

  • Delayed diagnosis and limited antifungal access worsen outcomes

➡ This is one of the most important papers in the list for public health, service planning, and advocacy.


2. Invasive Aspergillosis in Intensive Care (including COVID-19)

Clinical spectrum of ICU-acquired invasive pulmonary aspergillosis according to SARS-CoV-2 infection
Eur J Clin Microbiol Infect Dis, Jan 2026

Why this is important

  • Large prospective multicentre ICU cohort

  • Builds on lessons from COVID-19 Associated Pulmonary Aspergillosis (CAPA)

Key messages

  • ICU-acquired aspergillosis remains common and deadly

  • COVID-19 patients are typically older and more severely ill

  • Early fungal testing in ICU is critical

➡ High relevance for intensivists, respiratory teams, and hospital policy.


3. Drug interactions in invasive aspergillosis

Concurrent administration of triazoles with chemotherapeutic and/or immunosuppressant agents
Mycopathologia, Jan 2026

Why this is important

  • Addresses real-world prescribing risk

  • Highly relevant to cancer, transplant, and haematology patients

Key messages

  • Triazole antifungals cause clinically dangerous drug–drug interactions

  • Requires specialist pharmacy oversight and monitoring

  • Not theoretical – directly affects patient safety

➡ High importance for clinicians and pharmacists, less so for patients directly, but critical for safe care.


🟧 MODERATE IMPACT / CLINICALLY INFORMATIVE

(Important, but narrower scope or smaller evidence base)


4. Aspergillosis beyond the “immunocompromised”

Pulmonary fungal infections in the immunocompetent host
Chest, Jan 2026 – Review

Why this matters

  • Challenges outdated assumptions

  • Useful for GPs and general physicians

Key messages

  • Serious fungal lung disease can occur without classic immune suppression

  • Chronic lung disease, viral infection, or exposure can be sufficient

  • Supports earlier fungal consideration when antibiotics fail

➡ Good educational review, especially for non-specialists.


5. Aspergillus species diversity and resistance

Beyond Fumigatus: a molecular portrait of clinical Aspergillus diversity
Antimicrobial Agents and Chemotherapy, Jan 2026

Why this matters

  • Advances understanding of non-fumigatus Aspergillus

  • Relevant to antifungal resistance

Key messages

  • Aspergillosis is caused by multiple species

  • Species identification may influence treatment success

  • Supports move toward precision mycology

➡ Important scientifically, indirect impact for patients (for now).


6. Minimally invasive treatment of aspergilloma

Minimally invasive management of a centrally located pulmonary aspergilloma
MMCTS, Jan 2026

Why this matters

  • Demonstrates evolving surgical approaches

  • Relevant to selected patients only

Key messages

  • Less invasive procedures may reduce surgical risk

  • Careful patient selection is crucial

➡ Clinically interesting, but case-based and niche.


🟨 LOW IMPACT / EARLY-STAGE / NICHE

(Useful context or future potential, limited immediate impact)


7. ABPA immunology and diagnostics (early-stage science)

Pathogen-specific IgE-reactive cytosolic allergenic epitopes of Aspergillus fumigatus
Ann Clin Microbiol Antimicrob, Jan 2026

Why this matters

  • Laboratory-based discovery research

Key messages

  • May improve future ABPA diagnostics

  • Potential foundation for targeted immunotherapy

➡ Promising but not practice-changing yet.


8. Voriconazole neurotoxicity (single case)

Voriconazole-associated peripheral polyneuropathy: A case report
Arch Argent Pediatr, Feb 2026

Why this matters

  • Highlights a rare but serious adverse effect

Key messages

  • Neurological symptoms on antifungals should not be ignored

  • Reinforces importance of monitoring during long-term therapy

➡ Low evidence level, but high awareness value.


9. Invasive aspergillosis in complex transplant oncology case

An Unforeseen Diagnosis After Liver Transplantation for Acute Liver Failure
Case Reports in Hepatology, Jan 2026

Why this matters

  • Illustrates diagnostic complexity in extreme immunosuppression

Key messages

  • Invasive aspergillosis can be rapidly fatal

  • Symptoms may be masked by other conditions

➡ Educational case, not generalisable.


10. Food enzyme safety (non-clinical)

Safety evaluation of the food enzyme aspergillopepsin I
EFSA Journal, Jan 2026

Why this matters

  • Addresses public concern rather than clinical disease

Key messages

  • Aspergillus-derived food enzymes are safe when regulated

  • Dietary exposure ≠ inhaled fungal spores

➡ Reassuring, but peripheral to aspergillosis care.


🔑 Overall “Most Important” Papers (Quick List)

Top tier

  1. CPA outcomes and mortality (Brazil cohort)

  2. ICU / COVID-19 associated invasive aspergillosis

  3. Triazole drug–drug interactions

Second tier
4. Fungal infection in immunocompetent hosts
5. Aspergillus species diversity & resistance

January–February 2026 Aspergillosis Papers – Source Links

🟥 High-impact / practice-relevant

  • Clinical Features and Mortality of Chronic Pulmonary Aspergillosis in Brazil: a Multicenter Cohort Study
    de Oliveira VF et al., Open Forum Infectious Diseases, Jan 2026
    🔗 https://pubmed.ncbi.nlm.nih.gov/41536616/

  • Clinical spectrum of ICU-acquired invasive pulmonary aspergillosis according to SARS-CoV-2 infection: a multicenter prospective cohort study
    Reizine F et al., European Journal of Clinical Microbiology & Infectious Diseases, Jan 2026
    🔗 https://pubmed.ncbi.nlm.nih.gov/41526761/

  • Concurrent Administration of Triazoles with Chemotherapeutic and/or Immunosuppressant Agents Known to Have Moderate-to-Severe Drug-Drug Interactions in Patients with Hematologic Malignancies Hospitalized for Invasive Aspergillosis
    Walsh TJ et al., Mycopathologia, Jan 2026
    🔗 https://pubmed.ncbi.nlm.nih.gov/41528615/


🟧 Moderate-impact / clinically informative


🟨 Lower-impact / niche / early-stage

  • Pathogen-specific IgE-reactive cytosolic allergenic epitopes of Aspergillus fumigatus for immunodiagnostic and immunotherapeutic applications against allergic aspergillosis
    Koundal P et al., Annals of Clinical Microbiology and Antimicrobials, Jan 2026
    🔗 https://pubmed.ncbi.nlm.nih.gov/41540426/

  • Voriconazole-associated peripheral polyneuropathy: A case report
    González BJ et al., Archivos Argentinos de Pediatría, Feb 2026
    🔗 https://pubmed.ncbi.nlm.nih.gov/40728252/

  • An Unforeseen Diagnosis After Liver Transplantation for Acute Liver Failure: Extranodal NK/T-Cell Lymphoma (includes invasive aspergillosis)
    Soares GL et al., Case Reports in Hepatology, Jan 2026
    🔗 https://pubmed.ncbi.nlm.nih.gov/41542139/

  • Safety evaluation of the food enzyme aspergillopepsin I from the genetically modified Trichoderma reesei strain DP-Nzq40
    EFSA Panel on Food Enzymes, EFSA Journal, Jan 2026
    🔗 https://pubmed.ncbi.nlm.nih.gov/41531469/


What’s New in Aspergillosis Clinical Trials (Last ~4 Months)

An overview for patients and non-specialist readers — 19 January 2026

Over the past four months, research into aspergillosis — including chronic, allergic, and invasive forms — has continued across a range of clinical trials. These studies include treatments, diagnostics, and better ways to understand who gets sick and how best to manage it.

Below is a summary of the most relevant trials now active, recruiting, or updated recently. Whenever possible, we link to the official ClinicalTrials.gov record so you can see the details, eligibility criteria, locations, and contact information.


📋 Clinical Trials of Interest

1. Phase III Olorofim Trial for Invasive Aspergillosis

Study title: Olorofim Aspergillus Infection Study
Condition: Invasive aspergillosis (IA)
What it’s testing: A new antifungal drug called olorofim compared with liposomal amphotericin B followed by standard care.
Status: Active — not currently recruiting new patients but ongoing through 2026.
Official record: Olorofim Aspergillus Infection Study on ClinicalTrials.gov
Last updated: January 4, 2026
Why this matters: Olorofim is a completely new class of antifungal designed for patients whose infection is difficult to treat with standard drugs. It may offer an alternative for those with drug-resistant or treatment-intolerant infections.


2. Rezafungin in Chronic Pulmonary Aspergillosis (CPA)

Study title: Rezafungin for Treatment of Chronic Pulmonary Aspergillosis
Condition: Chronic pulmonary aspergillosis
What it’s testing: A long-acting echinocandin antifungal (rezafungin) that might reduce dosing frequency.
Status: Recruiting / active
Official record: Rezafungin CPA Trial on ClinicalTrials.gov
Why this matters: Current CPA treatments can require daily medication and prolonged therapy. Rezafungin’s once-weekly dosing could help reduce burden and hospital visits.


3. Combination Trial: Ibrexafungerp + Voriconazole (SCYNERGIA)

Study title: Evaluate Safety and Efficacy of Ibrexafungerp With Voriconazole in Invasive Pulmonary Aspergillosis
Condition: Invasive pulmonary aspergillosis
What it’s testing: Whether combining two antifungals works better than standard therapy alone.
Status: Active (ongoing)
Official record: SCYNERGIA Combination Trial on ClinicalTrials.gov
Why this matters: Some patients don’t respond well to single-agent treatment. Combination therapy may help in severe cases, especially where resistance is a concern.


4. PCR Diagnostic Study for Aspergillus fumigatus

Study title: PCR for Aspergillus Fumigatus in Blood and Bronchoalveolar Lavage Fluid
Condition: Aspergillosis (diagnostic focus)
What it’s testing: A blood and lung fluid PCR test to improve early detection of aspergillosis.
Status: Recruiting
Official record: PCR Aspergillus fumigatus Diagnostic Trial on ClinicalTrials.gov
First posted: 2 January 2026
Why this matters: Early diagnosis increases the chance of successful treatment. A reliable PCR test could allow clinicians to start antifungal therapy sooner.


🔎 What Else Is Ongoing?

There are other studies that include aspergillosis patients or Aspergillus exposure as part of broader research, such as:

  • All-of-Us Research Program fungal infection analysis — large observational work looking at fungal disease patterns in hundreds of thousands of people in the U.S., including aspergillosis. (Not a clinical trial per se but relevant to understanding how aspergillosis affects populations.)

  • Historic or related trials — e.g., older isavuconazole comparisons (e.g., NCT00412893) exist but are not newly updated.


🧠 What This Means for Patients

  • New antifungal drugs like olorofim and rezafungin are being tested in late-stage studies — these could expand treatment options in the future.

  • Combination therapies (e.g., ibrexafungerp + voriconazole) are being assessed to tackle difficult or resistant infections.

  • Improved diagnostics (e.g., PCR tests for Aspergillus fumigatus) are now being studied to help clinicians diagnose infections earlier and more accurately.

  • Not all trials are about treatment — some focus on better ways to detect infection or understand disease patterns, which are important for prevention and clinical practice.


🗓 How to Use These Links

Clicking a trial link takes you to the official ClinicalTrials.gov page, where you can often see:

  • Who can participate

  • Locations and contact information

  • Detailed eligibility criteria

  • Sponsor and trial timelines

If you have questions about joining a trial or how it applies to you specifically, always discuss this with your healthcare team.


Indoor Damp, Ventilation & Aspergillosis

What a Major UK Evidence Review Means for Patients and Professionals

Why this paper matters

This large UK Health and Safety Executive (HSE) review examined whether microorganisms inside buildings (homes, offices, workplaces) can harm health — and what actually helps reduce risk.

Although it does not focus on a single disease, its findings are highly relevant to people living with aspergillosis, asthma, bronchiectasis, and other chronic lung conditions, as well as the professionals who support them.

Link to paper


The short answer (for everyone)

Yes — indoor environments can significantly affect lung health.
And ventilation and moisture control are central to reducing risk, especially for people vulnerable to fungal exposure.


What the review confirms (in plain language)

1. Indoor fungi are common — and not harmless

High confidence evidence

Many buildings contain airborne and surface fungi, especially when dampness is present.
The fungi most often found indoors include:

  • Aspergillus

  • Penicillium

  • Cladosporium

  • Alternaria

For aspergillosis patients, this matters because:

  • Aspergillus is not just an “outdoor mould”

  • Ongoing exposure can worsen symptoms, trigger inflammation, or complicate recovery

  • Even low levels may be problematic for sensitised or immunocompromised people


2. Dampness is a major driver of fungal exposure

High confidence

Damp buildings — whether due to leaks, condensation, or poor airflow — consistently show:

  • Higher mould growth

  • More fungal spores in the air

  • Stronger links to respiratory symptoms

Important point for patients:

You do not need to see black mould for damp to be affecting your lungs.
Mould smell (“musty odour”) is one of the strongest warning signs.


3. Ventilation is the most important protective factor

High confidence

Ventilation:

  • Dilutes fungal spores, bacteria, and viruses

  • Reduces moisture build-up

  • Lowers exposure for occupants

This applies to:

  • Homes

  • Flats

  • Offices

  • Other non-industrial indoor spaces

⚠️ The review highlights a key modern problem:
Energy-efficient, airtight buildings can unintentionally trap damp and fungi if ventilation is inadequate.

For aspergillosis patients, this means:

  • A “warm” home is not always a “healthy” home

  • Reduced airflow can increase fungal exposure even without visible mould


4. Indoor air also spreads infections

High confidence

Respiratory viruses (e.g. influenza, COVID-19) spread mainly through indoor air, especially when ventilation is poor.

This is relevant for aspergillosis patients because:

  • Viral infections can destabilise lung disease

  • Recovery may be slower

  • Secondary infections are more likely

Ventilation therefore protects against both fungal and viral risks.


5. Surfaces matter too — but air matters more

Medium–high confidence

  • Fungal material and microbes accumulate in dust, carpets, soft furnishings, and damp surfaces

  • Toilets and bathrooms can generate contaminated aerosols

  • Good hygiene helps, but cannot compensate for poor ventilation

For patients:

Cleaning alone will not solve a damp or ventilation problem.


What actually helps (evidence-based)

Strongest evidence

✔️ Adequate ventilation (natural or mechanical)
✔️ Fixing leaks and moisture sources
✔️ Removing mould-damaged materials
✔️ Preventing condensation on cold surfaces

Moderate evidence

✔️ HEPA air filtration (helpful but not a substitute for ventilation)
✔️ UV air disinfection (context-specific)
✔️ Touch-free fittings in shared buildings

⚠️ No single measure works on its own — combined approaches are needed.


Why this matters specifically for aspergillosis patients

This review strongly supports what many patients already experience:

  • Symptoms may persist despite treatment if exposure continues

  • Indoor environments can drive inflammation and relapse

  • “Just take your medication” is not enough if housing conditions are harmful

Importantly, the review recognises that:

  • Health effects vary by individual vulnerability

  • Those with asthma, bronchiectasis, aspergillosis, or immune suppression are more sensitive

  • There are no universally safe mould levels for everyone


What non-specialists should take from this

For GPs and clinicians

  • Damp and poor ventilation are legitimate medical risk factors

  • Persistent respiratory symptoms may be environment-driven

  • Asking about housing conditions is clinically relevant

For housing, environmental health & social care

  • Mould and damp are health hazards, not cosmetic defects

  • Ventilation failures can directly affect chronic disease

  • Energy efficiency must be balanced with respiratory health

For patients and carers

  • You are not “overreacting” if your home affects your breathing

  • Ventilation and moisture control are part of disease management

  • Evidence supports advocating for safer living conditions


Bottom line

This major UK review confirms that indoor dampness and poor ventilation increase exposure to fungi — including Aspergillus — and worsen respiratory health.
For people living with aspergillosis, building conditions are not secondary issues: they are part of the disease environment.


How to Ask Fewer, Better Questions in Appointments

Focusing on what matters most to you—without feeling you’re wasting time

Many patients and carers worry about “asking too much” in clinic. Appointments are short, clinicians are busy, and you may already have a long list of questions in your head. The aim isn’t to stop asking questions—it’s to ask the right ones, at the right time, in the right way.

Here are practical strategies that help you stay focused, feel heard, and make the most of limited time.


1. Decide your Top 3 priorities before you go

Before the appointment, write down everything you’re thinking about. Then circle just three things that matter most right now.

Good priorities are usually:

  • A symptom that is new, worsening, or frightening

  • A treatment issue that affects daily life (side-effects, adherence, cost, function)

  • A decision you need to make soon

If it doesn’t change what happens in the next few weeks, it may not need airtime today.

If you remember only one thing: appointments are for decisions, not encyclopaedias.


2. Separate “need to know” from “nice to know”

It’s easy to mix curiosity with urgency.

Need to know (ask now):

  • Is this symptom important?

  • Is this treatment still right for me?

  • What should I do if X happens?

  • Are we monitoring the right things?

Nice to know (park for later):

  • Mechanisms, pathways, emerging research

  • Rare side-effects without symptoms

  • “What if” scenarios far in the future

Keep a “parking list” for later reading or discussion.


3. Frame questions around impact, not theory

Clinicians work best when questions are grounded in real life.

Instead of:

  • “I read a paper saying X might affect Y…”

Try:

  • “I’m noticing X in daily life—does that change what we do?”

  • “Is this symptom something you’d want to investigate?”

This signals relevance and helps clinicians triage quickly.


4. Ask one question at a time

Long, multi-part questions feel overwhelming and are easy to partially answer.

Break them down:

  • First: Is this important?

  • Then (if yes): What do we do about it?

  • Then (if needed): What should I watch for?

You’ll often find later questions become unnecessary once the first is answered.


5. Use the “Is this something we should…” test

This single phrase keeps questions concise and respectful of time:

  • “Is this something we should investigate?”

  • “Is this something that changes treatment?”

  • “Is this something I should worry about?”

A clear yes/no (or not yet) is often all you need.


6. Accept that not everything fits in one appointment

It’s okay—and normal—to say:

  • “I know we may not have time today—what should I prioritise?”

  • “Which of these matters most from your point of view?”

This shows partnership, not passivity.

If something needs more time, ask how best to handle it:

  • Another appointment

  • A nurse specialist

  • Written advice

  • Monitoring and review later


7. Bring written notes (but don’t read them all out)

A short list helps you stay focused under pressure.

Tip:

  • Highlight your top 3

  • Tick them off as they’re addressed

  • If time runs out, you still covered what mattered most


8. For carers: ask on behalf, not over

Carers often worry about dominating the conversation.

Helpful approaches:

  • Ask the patient first: “What do you most want answered today?”

  • Step in only if something important is being missed

  • Offer to follow up questions outside the appointment if possible


9. Reassure yourself: clinicians don’t expect perfection

You are not expected to:

  • Understand everything

  • Ask the “right” questions every time

  • Cover your entire condition in one visit

Good clinicians prefer:

a focused conversation
over
a rushed, overloaded one


10. A simple closing question that saves time

If time is tight, end with:

  • “Is there anything you think I should have asked but didn’t?”

This often surfaces the most important point of all.


The takeaway

You are not wasting time by asking questions—you’re wasting time by asking too many unfocused ones.

Clarity, prioritisation, and relevance help everyone:

  • You leave with answers that matter

  • Clinicians can make better decisions

  • Anxiety is reduced, not fuelled


Learning About Aspergillosis (and Related Treatments)

How to stay curious, informed, and safe — without overload

Many people living with aspergillosis, or caring for someone who is, become highly motivated learners. You may read scientific papers, books, online articles, social media posts, AI summaries, and news stories about antifungal treatments, steroids, biologics, side-effects, immunity, mould exposure, diet, exercise, and wellbeing.

That curiosity is a strength. It helps you ask better questions, notice changes early, and feel more involved in your care.

At the same time, not all information is reliable, relevant, or helpful, and even good information can become harmful if it is over-interpreted or taken out of context. This article is about finding the balance: learning with confidence, without increasing anxiety or risk.


Why learning helps — and why it can sometimes backfire

The positives

  • Empowerment: Understanding your condition improves confidence.

  • Better conversations: Appointments are more productive when you share a common language.

  • Early awareness: You may recognise symptoms or side-effects sooner.

  • Reassurance: Knowledge can reduce uncertainty and fear.

The risks

  • Over-interpretation: A single paper or post can feel more important than it is.

  • Variable quality: Some research is weak, outdated, biased, or misapplied.

  • Loss of context: Lab studies or rare case reports may not apply to you.

  • Rising anxiety: Constant searching can amplify worry rather than reduce it.

  • Information overload: Too much input can make decisions harder, not easier.


A healthier approach to learning

1. Think in weight of evidence, not single findings

One article, story, or AI answer almost never changes medical care on its own.

When you read something new, ask:

  • Is this supported by more than one study?

  • Does it appear in guidelines or specialist practice?

  • Is it discussed cautiously, or presented as a breakthrough?

A useful rule of thumb:

The more dramatic the claim, the stronger the evidence needs to be.


2. Separate biological possibility from clinical reality

Many things are biologically plausible — immune pathways, hormones, inflammation, the microbiome — but that doesn’t mean they are proven or clinically relevant.

Helpful questions include:

  • Was this studied in people, or only in the lab?

  • Were the patients similar to me?

  • Did it improve symptoms or outcomes, not just blood tests?


Choosing trusted health information: practical guidance

Learning safely isn’t about reading less. It’s about choosing better sources and knowing how much weight to give them.

3. Start with sources that anchor practice

Your most reliable foundations are sources that:

  • Reflect clinical consensus, not speculation

  • Are written or reviewed by specialist teams

  • Change slowly because they are evidence-based

Examples include:

  • Specialist centre or hospital websites

  • National or international guidelines

  • Established patient organisations linked to clinical services

Examples:

    • NHS website
      A good starting point for clear, balanced information on symptoms, tests, treatments, and general health advice.
      Useful for understanding what is considered standard care in the UK.

    • British National Formulary (BNF)
      The main UK reference for medicines.
      Particularly helpful for:

      • Medication side-effects

      • Drug interactions (including antifungals, steroids, and inhalers)

      • Practical prescribing information
        Side-effects are listed cautiously, so not everything applies to every person.

    • aspergillosis.org
      A specialist resource focused specifically on aspergillosis, written for patients, carers, and professionals.
      Helpful for understanding different forms of aspergillosis, investigations, treatments, and living with the condition.

    • European Lung Foundation – Aspergillosis resources
      Patient-focused information developed with respiratory specialists and patient representatives across Europe.
      Particularly useful for:

      • Plain-language explanations

      • Patient priorities and lived experience

      • Shared decision-making and questions to ask in clinic

    • Asthma + Lung UK (BLF)
      A trusted source for asthma and other lung diseases.
      Helpful for inhaler use, breathlessness, flare-ups, lifestyle advice, and living well with chronic lung conditions.

    • Aspergillosis Trust
      This website was created by patients who suffer from Aspergillosis. Please navigate around the website to read more about this disease, also the impact it has upon patients and their carers.

These sources may feel less exciting — but they set the safe boundaries of what is known.


4. Learn to spot interpretation versus evidence

Two people can read the same paper and draw very different conclusions.

Ask yourself:

  • Is this source presenting evidence, or interpreting it strongly?

  • Are limitations and uncertainty acknowledged?

  • Is the language careful or absolute?

Trusted sources often say:

“Evidence suggests…” or “We don’t yet know…”

Less reliable ones often say:

“This proves…” or “This explains everything.”


5. Use a simple credibility checklist

You don’t need to be a scientist to judge quality.

When reading anything, consider:

Who wrote it?
Clinical specialists, recognised organisations, or anonymous individuals?

Why was it written?
To inform and support — or to sell, persuade, or provoke?

What evidence is used?
Multiple studies and guidelines — or a single paper or personal story?

What tone is used?
Balanced and cautious — or dramatic and fear-based?

Several warning signs together should lower confidence.


6. Be cautious with “hidden” or “overlooked” explanations

Phrases that should trigger caution include:

  • “Doctors don’t tell you this…”

  • “The hidden cause…”

  • “The real reason…”

  • “One simple explanation…”

Conditions like aspergillosis are complex. Simple, universal explanations are rarely accurate.


7. Understand where research sits on the evidence ladder

Not all research carries the same weight.

Very roughly:

  1. Clinical guidelines and consensus statements

  2. Large clinical trials and systematic reviews

  3. Observational studies

  4. Case reports

  5. Laboratory or animal studies

  6. Opinions and anecdotes

Lower down the ladder does not mean “worthless” — but it does mean less certain and less likely to change care on its own.


8. Treat patient stories and forums as experience, not prediction

Patient experiences are invaluable for:

  • Feeling less alone

  • Understanding day-to-day challenges

  • Sharing coping strategies

They are not reliable predictors of:

  • What will happen to you

  • How common a problem is

  • Whether a treatment will help or harm you

A helpful distinction:

Stories help you feel understood. Evidence helps guide decisions.


9. Use AI tools wisely

AI can be excellent for:

  • Explaining terminology

  • Summarising broad topics

  • Helping you generate questions

AI cannot:

  • Replace specialist judgement

  • Fully understand your medical history

  • Balance risk in the way clinicians do

Treat AI as:

“A map to the topic,”
not
“An answer about me.”


10. Limit your sources — and give yourself permission to stop

Many people feel calmer once they:

  • Choose two to four trusted sources

  • Revisit those instead of endlessly searching

  • Accept that not every new paper needs action

Stopping is not giving up — it is protecting your wellbeing.


Bringing what you’ve learned into clinic

A good sign you’ve chosen reliable information:

  • You feel comfortable sharing it with clinicians

  • It leads to discussion, not confusion

  • It helps prioritise decisions

You might say:

  • “I’ve been reading from a specialist source — how relevant is this to me?”

  • “This helped me understand X, but I’m not sure how much weight to give it.”


When to pause or rebalance your learning

Consider stepping back if:

  • Searching increases anxiety every time

  • You feel pressure to solve everything yourself

  • Conflicting information leaves you stuck

  • Illness becomes the only thing you think about

Taking breaks from research is not disengagement — it is self-care.


The key message

Learning is a powerful tool. Used well, it supports confidence, partnership, and resilience. Used without guardrails, it can undermine peace of mind.

Aim for:

  • Curiosity with caution

  • Knowledge with context

  • Questions with balance

You don’t need to know everything.
You need to know what helps you live well and safely.


This article pairs with:
“Making the Most of Appointments: Asking Fewer, Better Questions” — a practical guide to deciding what to raise in clinic and how to use limited time effectively.


Recent Aspergillosis Research – January 2026 (week 2)

A curated update with direct links to the evidence


Allergic Bronchopulmonary Aspergillosis (ABPA) and Aspergillus Airway Disease

Several recent papers continue to refine how ABPA is diagnosed and managed, particularly outside classic asthma and cystic fibrosis settings.

A practical treatment overview for ABPA in cystic fibrosis is provided by Thimmesch et al., focusing on steroid strategies and antifungal use
👉 https://pubmed.ncbi.nlm.nih.gov/41537324/

A major narrative review of ABPA and Aspergillus-related airway disease in bronchiectasis reframes ABPA as part of a wider spectrum of Aspergillus-driven lung disease, with implications for earlier recognition
👉 https://pubmed.ncbi.nlm.nih.gov/41522133/

Diagnostic uncertainty remains a major challenge. A comparative study of IgG/IgE ELISA versus serum precipitins highlights strengths and limitations of commonly used tests
👉 https://pubmed.ncbi.nlm.nih.gov/41514182/

Treatment optimisation is addressed in a retrospective cohort study examining glucocorticoid dose, duration, and antifungal combinations in ABPA, showing that regimen choice meaningfully affects outcomes
👉 https://pubmed.ncbi.nlm.nih.gov/41492771/

ABPA is increasingly recognised beyond asthma and cystic fibrosis. A short but influential paper proposes Aspergillus sensitisation and ABPA in COPD as a “treatable trait”
👉 https://pubmed.ncbi.nlm.nih.gov/41520264/

Rare but clinically important overlap is illustrated by a case report describing invasive pulmonary aspergillosis overlapping with ABPA
👉 https://pubmed.ncbi.nlm.nih.gov/41496036/


Chronic Pulmonary Aspergillosis (CPA) and Aspergilloma

A large multicentre cohort study from Brazil provides valuable data on CPA in high tuberculosis-burden settings, documenting delayed diagnosis and significant mortality
👉 https://pubmed.ncbi.nlm.nih.gov/41536616/

Surgical innovation is highlighted in a report describing minimally invasive management of a centrally located pulmonary aspergilloma in an adolescent, showing evolving interventional approaches
👉 https://pubmed.ncbi.nlm.nih.gov/41537646/

CPA caused by non-fumigatus species is increasingly recognised, including a case of Aspergillus candidus infection in a lung cancer patient with heavy smoking history
👉 https://pubmed.ncbi.nlm.nih.gov/41495698/


Invasive Pulmonary Aspergillosis (IPA): Expanding Risk Groups

A comprehensive review describes how IPA is increasingly seen in non-neutropenic patients, challenging traditional risk models
👉 https://pubmed.ncbi.nlm.nih.gov/41515529/

ICU-acquired IPA is examined in a large multicentre cohort stratified by SARS-CoV-2 infection, demonstrating different clinical patterns in COVID-positive and COVID-negative patients
👉 https://pubmed.ncbi.nlm.nih.gov/41526761/

Longitudinal mycological data from ICU patients with influenza- and COVID-associated pulmonary aspergillosis (IAPA and CAPA) show how bronchoalveolar lavage galactomannan kinetics relate to outcome
👉 https://pubmed.ncbi.nlm.nih.gov/41508132/

IPA is not confined to traditional risk groups. A case report documents invasive aspergillosis in a child without identifiable risk factors, reinforcing the need for diagnostic vigilance
👉 https://pubmed.ncbi.nlm.nih.gov/41520716/

Rare manifestations continue to appear, including isolated renal aspergillosis after paediatric stem-cell transplantation
👉 https://pubmed.ncbi.nlm.nih.gov/41508322/


Diagnostics, Resistance, and Drug Safety

Concerns about antifungal resistance are reinforced by a clinical screening study demonstrating azole resistance in Aspergillus isolates
👉 https://pubmed.ncbi.nlm.nih.gov/41528781/

A molecular overview of clinical Aspergillus diversity beyond A. fumigatus highlights implications for pathogenicity and antifungal susceptibility
👉 https://pubmed.ncbi.nlm.nih.gov/41528247/

Drug–drug interactions are explored in depth in a study examining concurrent triazole use with chemotherapy and immunosuppressants in invasive aspergillosis, underlining the importance of monitoring
👉 https://pubmed.ncbi.nlm.nih.gov/41528615/

Unusual but serious adverse effects are illustrated by a case of voriconazole-induced hypoglycaemia in a non-diabetic patient
👉 https://pubmed.ncbi.nlm.nih.gov/41506798/

Cutaneous manifestations as early diagnostic clues are reviewed in a paper on skin signs of invasive fungal disease, including secondary cutaneous aspergillosis
👉 https://pubmed.ncbi.nlm.nih.gov/41505800/


New Therapies and Prevention Strategies

A nationwide French observational study reports real-world outcomes from compassionate use of olorofim in invasive mould infections, including refractory aspergillosis
👉 https://pubmed.ncbi.nlm.nih.gov/41531505/

Economic evidence is emerging alongside clinical data. A cost-utility analysis of preventing invasive aspergillosis in lung transplant recipients supports targeted prophylactic strategies
👉 https://pubmed.ncbi.nlm.nih.gov/41490563/


Fundamental and Translational Aspergillus Research

Several papers advance understanding of Aspergillus fumigatus virulence and regulation, including network-based gene regulation models
👉 https://pubmed.ncbi.nlm.nih.gov/41505094/

A detailed mechanistic study shows how CsdA–LaeB regulatory interactions influence virulence and secondary metabolite production
👉 https://pubmed.ncbi.nlm.nih.gov/41498629/

Vaccine-relevant work explores how cell-wall remodelling alters innate immune recognition in an experimental A. fumigatus strain
👉 https://pubmed.ncbi.nlm.nih.gov/41509434/

Population genomics continues to redefine Aspergillus diversity, including the Aspergillus flavus–oryzae complex, with relevance to both clinical and environmental exposure
👉 https://pubmed.ncbi.nlm.nih.gov/41522572/


One Health and Veterinary Aspergillosis

Aspergillosis remains a One-Health issue, with reports including fungal pericarditis due to Aspergillus fumigatus in dogs
👉 https://pubmed.ncbi.nlm.nih.gov/41521069/

and Aspergillus infections in endangered bird species, highlighting environmental and conservation links
👉 https://pubmed.ncbi.nlm.nih.gov/41497419/


Sinusitis in Patients with ABPA

When to suspect it, when to investigate, and when to refer

Looking for general information about fungal sinus disease? See our Fungal Rhinosinusitis guide for information about AFRS, fungal ball, fungal colonisation and invasive fungal rhinosinusitis.


Why this matters

Patients with allergic bronchopulmonary aspergillosis (ABPA) are usually managed as having a lung disease. Diagnosis, monitoring, and treatment focus appropriately on the chest, immunology, and asthma control.

However, ABPA occurs within a single continuous airway, extending from the nose and sinuses to the lungs. Disease in the upper airway can coexist with, exacerbate, or complicate lower airway inflammation — yet sinus disease is not routinely assessed in ABPA care pathways.

This article outlines:

  • What is known about sinus disease in this context

  • Which symptoms should raise suspicion

  • When investigation or ENT referral should be considered

  • What GPs and non-specialists can reasonably do


The united airway: a brief reminder

The upper and lower airways share:

  • Type 2 (eosinophilic) inflammation

  • Immunoglobulin E–mediated immune responses

  • Common triggers, including allergens and fungi

Chronic rhinosinusitis is common in asthma and severe asthma, and treatment of sinus disease can improve lower airway outcomes in some patients.
ABPA sits within this same inflammatory spectrum, even though its management is lung-centred.


Sinus disease in ABPA: what is (and isn’t) known

What we know

  • Chronic rhinosinusitis is common in patients with asthma and severe asthma

  • Sinus disease may be symptomatic or relatively silent

  • ABPA guidelines do not mandate routine ENT review or sinus imaging

  • ENT involvement, therefore, varies widely between centres

What we do not know

  • Whether routine ENT assessment improves ABPA outcomes

  • Which ABPA patients benefit most from sinus intervention

  • The optimal timing for ENT referral in ABPA

As a result, clinical judgement remains central.


Symptoms that should prompt consideration of sinus disease

Sinusitis in ABPA patients does not always present with classic “blocked nose and facial pain”.
Key symptoms include:

Common but often overlooked

  • Persistent post-nasal drip

  • Foul, bitter, metallic, or “infected” taste in the mouth

  • Throat clearing, chronic cough

  • Thick or sticky mucus sensation

  • Symptoms are worse on waking or lying flat

More typical sinonasal features

  • Nasal blockage or congestion

  • Facial pressure or fullness

  • Reduced or altered sense of smell

  • Nasal crusting or discharge

Contextual clues

  • Poor durability of response to steroids or antifungals

  • Recurrent “flares” without clear chest triggers

  • Coexisting severe asthma or nasal polyps

  • Symptoms are worse in damp or mould-affected housing

A persistent foul taste in the mouth is a recognised symptom of chronic sinus disease, usually due to post-nasal drainage of inflamed secretions.


Damp homes and sinus disease

Living in damp or mould-affected environments is associated with:

  • Higher rates of chronic rhinosinusitis

  • Upper airway irritation and inflammation

  • Allergic sensitisation to fungal spores

In most cases, this results in inflammatory or allergic sinusitis, not invasive fungal infection.
Fungal involvement may act as an immune trigger, even when not labelled as “fungal sinusitis”.


Fungal sinusitis: rare vs under-recognised

It is important to distinguish between entities:

Type Frequency Key point
Invasive fungal sinusitis Rare Usually immunocompromised; dramatic presentation
Fungal ball (mycetoma) Uncommon Usually obvious on CT
Allergic fungal rhinosinusitis Likely under-recognised Requires active suspicion

Allergic fungal rhinosinusitis overlaps biologically with ABPA:

  • IgE-mediated

  • Eosinophilic inflammation

  • Thick allergic mucin

It is not routinely sought, so it may be under-diagnosed in at-risk groups.


What GPs and non-specialists can reasonably do

1. Take upper airway symptoms seriously

Especially in ABPA or severe asthma patients with:

  • Persistent post-nasal symptoms

  • Foul taste

  • Recurrent unexplained deterioration

2. Examine the nose and throat

  • Look for polyps, discharge, and crusting

  • Note mouth breathing or altered voice quality

  • Check dentition (to exclude dental causes)

3. Consider imaging when symptoms persist

  • CT sinuses (not plain X-ray) is the imaging of choice

  • Particularly appropriate if symptoms last >8–12 weeks or recur

4. Refer to ENT when:

  • Symptoms are persistent or progressive

  • CT shows significant sinus disease

  • There is a poor response to standard medical therapy

  • There is diagnostic uncertainty

Referral does not imply surgery — ENT input may be diagnostic or medical.


What this article is not saying

  • It does not suggest that all ABPA patients need an ENT referral

  • It does not claim that sinus treatment improves ABPA outcomes

  • It does not override existing guidelines

It does suggest that earlier consideration of the upper airway is reasonable in selected patients.


Key take-home points for clinicians

  • The airway functions as a single inflammatory system

  • Sinus disease may be subtle, under-reported, or atypical

  • A foul taste in the mouth is a meaningful symptom

  • Damp or mould exposure increases sinus disease risk

  • ENT referral is appropriate when symptoms persist or recur

  • Evidence gaps remain — but clinical vigilance is justified


In summary

ABPA is managed as a lung disease, but patients live with a whole airway.
Recognising when sinus disease may be contributing can help explain persistent symptoms and guide appropriate referral — without over-investigation or over-treatment.